Definitive Contract HHSN261201300061C

<p>This is a cost-plus-fixed-fee SBIR Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to LP Therapeutics, Inc. for the development of novel therapeutic agents targeting cancer stem cells. The contract has a total ceiling value of $1,489,000.12 and a period of performance ending on March 18, 2019. The contract was set aside for small businesses. No information is provided about major subcontractors.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&amp;D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...

This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the &quot;SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM&quot; and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Celartia, Inc., a small disadvantaged business, for the development of a fully automated system for cell therapy processing. The contract has a period of performance from September 13, 2021 to June 12, 2022 and a ceiling value of $393,312. The contract was awarded under a total small business set-aside. The original...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lisata Therapeutics Inc. (doing business as Caladrius Biosciences) for the development of novel therapeutic agents that target cancer stem cells. The definitive, firm fixed-price contract has a total ceiling value of $4,378,214.00 and a completion date of June 20, 2018. The contract was set aside for small businesses.</p>

The National Cancer Institute awarded a $294,719 Firm Fixed Price Definitive Contract to Kiyatec Inc., a small business, for the development of a 3D human tumor co-culture system to accurately predict clinical efficacy. This Small Business Innovation Research (SBIR) Phase I contract was awarded on September 20, 2013, with a completion date of July 21, 2014. The contract was awarded under Topic 314 and aims to create a novel in vitro testing platform to improve the prediction of actual clinical...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...

<p>This is a $1,496,276.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellerant Therapeutics, Inc. The contract is for the SBIR (Small Business Innovation Research) Phase II development of novel therapeutic agents that target cancer stem cells, under Topic 326. The contract has a total small business set-aside designation and was awarded on September 19, 2016 with an ultimate completion date of April 16, 2018.</p>

<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>